Clint Pecenka
Overview
Explore the profile of Clint Pecenka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
600
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dvorkin J, Pecenka C, Sosa E, Sancilio A, Duenas K, Rodriguez A, et al.
BMJ Public Health
. 2025 Feb;
2(1):e000975.
PMID: 40018190
Introduction: There is lack of available data on the economic burden of wheezing episodes after severe respiratory syncytial virus (RSV) infection. This study aimed to assess the cost incurred for...
2.
Baral R, Amponsa-Achiano K, Barros I, Cofie P, Dapaah P, Fleming J, et al.
Vaccine
. 2025 Feb;
49:126769.
PMID: 39892111
Introduction: The maternal vaccine landscape is expanding, including the anticipated global rollout of the now approved respiratory syncytial virus maternal vaccine. Integrating maternal immunization (MI) into health systems in low-and...
3.
Baral R, Fleming J, Barros I, Cofie P, Dapaah P, Khan S, et al.
Vaccine
. 2024 Dec;
45:126654.
PMID: 39721352
Background: New vaccines for pregnant women have recently been introduced in some high-income countries to protect infants in early life. Implementing maternal immunisation (MI) successfully in low- and middle-income countries...
4.
Baral R, Knudson S, Barros I, Cofie P, Dapaah P, Khan S, et al.
Hum Vaccin Immunother
. 2024 Dec;
20(1):2437258.
PMID: 39687966
New respiratory syncytial virus (RSV) maternal vaccines have begun roll out in some countries, with efforts in progress to broaden access worldwide and shorten the timeline to access for low-...
5.
Debellut F, Bello G, Chisema M, Mkisi R, Kamzati M, Pecenka C, et al.
Vaccine X
. 2024 Dec;
21:100583.
PMID: 39633851
Malawi introduced typhoid conjugate vaccine (TCV) in 2023 through an integrated campaign delivering TCV alongside other vaccines and interventions (measles rubella vaccine (MRV), bivalent oral polio vaccine (OPV), and vitamin...
6.
Nguyen A, Sultana R, Vodicka E, Tasnim Z, Mehedi K, Islam M, et al.
Emerg Infect Dis
. 2024 Nov;
30(12):2593-2603.
PMID: 39592391
Japanese encephalitis (JE) is preventable using the affordable, effective, and safe live attenuated SA 14-14-2 JE vaccine (CD-JEV). We used a Markov model to evaluate the cost-effectiveness of 1 dose...
7.
Baral R, Otiang E, Odiyo J, Nyawanda B, Nyiro J, Munywoki P, et al.
BMJ Open
. 2024 Nov;
14(11):e084207.
PMID: 39578037
Objectives: To evaluate the cost of delivering childhood respiratory syncytial virus (RSV) prevention interventions to the health system in Kenya. Design: A prospective (cost projection) activity-based costing study. Setting: Kenya,...
8.
Guinazu G, Dvorkin J, Mahmud S, Baral R, Pecenka C, Libster R, et al.
Vaccine
. 2024 Oct;
44():126402.
PMID: 39362800
No abstract available.
9.
Pecenka C, Sparrow E, Feikin D, Srikantiah P, Darko D, Karikari-Boateng E, et al.
Lancet
. 2024 Sep;
404(10458):1157-1170.
PMID: 39265588
The search for safe and efficacious products to prevent severe respiratory syncytial virus (RSV) disease in young infants has lasted more than 60 years. In high-income and middle-income countries, two...
10.
Nyiro J, Nyawanda B, Mutunga M, Murunga N, Nokes D, Bigogo G, et al.
BMC Public Health
. 2024 Sep;
24(1):2410.
PMID: 39232690
Background: Respiratory syncytial virus (RSV) is one of the main causes of hospitalization for lower respiratory tract infection in children under five years of age globally. Maternal vaccines and monoclonal...